Adding Fluoxetine to Therapy Not Superior to Therapy Alone in Depressed Teens
The addition of fluoxetine to CBT did not further reduce depressive symptoms in young people with moderate-to-severe depression.
Stay updated with breaking news from Collaborative Medicinal Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The addition of fluoxetine to CBT did not further reduce depressive symptoms in young people with moderate-to-severe depression.
An international group of researchers explored possible explanations for why long-term users of antidepressants become chronically depressed.
Share this article Share this article ResearchAndMarkets.com's offering. Report Highlights The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 48, 62, 4, 224, 97 and 9 respectively. Similarly, the Universitie...